Zyla Life Sciences Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-11-12: Form 8-K; Period of report 2014-11-12; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2014-09-24: Form 8-K; Period of report 2014-09-23; Description 8.01 Other Events; Details 8.01.
- 2014-09-04: Form 8-K; Period of report 2014-09-04; Description 8.01 Other Events; Details 8.01.
- 2014-08-18: Form 8-K; Period of report 2014-08-18; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-11-12 | 8-K | 2014-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2014, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its third quarter ended September 30, 2014. | a14-24286_18k.htm |
| 2014-09-24 | 8-K | 2014-09-23 | 8.01 Other Events | 8.01 On September 23, 2014, Egalet Corporation issued a press release announcing an update on its clinical development plan for Egalet-001, a copy of which is filed herewith as Exhibit 99.1. | a14-21390_18k.htm |
| 2014-09-04 | 8-K | 2014-09-04 | 8.01 Other Events | 8.01 On September 4, 2014, Egalet Corporation issued a press release announcing data presentations from abuse-deterrence studies on Egalet-001, a copy of which is filed herewith as Exhibit 99.1. | a14-20466_18k.htm |
| 2014-08-18 | 8-K | 2014-08-18 | 8.01 Other Events | 8.01 On August 18, 2014, the Company issued a press release announcing the completion of an end-of-Phase 2 meeting with the U.S. Food and Drug Administration regarding Egalet-002, a copy of which is filed herewith as Exhibit 99.1. | a14-19202_18k.htm |
| 2014-08-14 | 8-K | 2014-08-13 | 7.01 Regulation FD Disclosure | 7.01 Representatives of Egalet Corporation (the “Company”) presented at the Canaccord Genuity Growth Conference on Wednesday, August 13, 2014 at 4:00 p.m. | a14-18535_38k.htm |
| 2014-08-12 | 8-K | 2014-08-12 | 2.02 Results of Operations and Financial Condition | 2.02 On August 12, 2014, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2014. | a14-18535_28k.htm |
| 2014-08-06 | 8-K | 2014-08-06 | 8.01 Other Events | 8.01 On August 6, 2014, the Company issued a press release announcing top-line results from bioequivalence studies for Egalet-001, a copy of which is filed herewith as Exhibit 99.1. | a14-18535_18k.htm |
| 2014-07-28 | 8-K | 2014-07-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (c) On July 28, 2014, Egalet Corporation (the “Company”) issued a press release announcing the appointment of Jeffrey M. Dayno, M.D., as the Company’s chief medical officer commencing July 31, 2014. | a14-17928_18k.htm |
| 2014-07-15 | 8-K | 2014-07-15 | 8.01 Other Events | 8.01 On July 15, 2014, the Company issued a press release announcing the results of its category one abuse deterrence studies for Egalet-001, a copy of which is filed herewith as Exhibit 99.1. | a14-17221_18k.htm |
| 2014-06-10 | 8-K | 2014-06-09 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2014 Annual Meeting of Stockholders (the “Annual Meeting”) of Egalet Corporation (the “Company”) was held on June 9, 2014. | a14-15159_18k.htm |
| 2014-05-13 | 8-K | 2014-05-13 | 2.02 Results of Operations and Financial Condition | 2.02 On May 13, 2014, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its first quarter ended March 31, 2014. | a14-12648_18k.htm |
| 2014-03-31 | 8-K | 2014-03-31 | 8.01 Other Events | 8.01 On March 31, 2014, the Company issued a press release announcing the results of its category one abuse deterrence studies for Egalet-001, a copy of which is filed herewith as Exhibit 99.1. | a14-9147_28k.htm |
| 2014-03-26 | 8-K | 2014-03-26 | 2.02 Results of Operations and Financial Condition | 2.02 On March 26, 2014, Egalet Corporation issued a press release announcing its financial results for its fourth quarter and year ended December 31, 2013. | a14-8969_18k.htm |
| 2014-03-11 | 8-K | 2014-03-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 (d) On March 10, 2014, the Board of Directors (the “Board”) of Egalet Corporation (the “Company”) expanded the Board to seven members and appointed Timothy P. Walbert as a Class C director of the Company. 8.01 On March 10, 2014, the Company issued a press release announcing the sale on March 7, 2014 of 630,000 shares of common stock for cash consideration of $12.00 per share (before underwriting discount) to a syndicate of underwriters pursuant to the underwriters’ exercise of their over-allotment option. | a14-7879_18k.htm |
| 2014-02-20 | 8-K | 2014-02-20 | 8.01 Other Events | 8.01 On February 20, 2014, Egalet Corporation (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track status for both Egalet-001, the Company’s lead product candidate, and Egalet-002, the Company’s second product candidate. | a14-6411_18k.htm |
| 2014-02-11 | 8-K | 2014-02-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.02 Effective February 5, 2014, Gregory Weaver has been appointed to the board of directors of Egalet Corporation (the “Company”), thereby joining Robert Radie, Andrey Kozlov, Andreas Rutger-Segerros, Jean-Francois Formela, Renee Aguiar Lucander. 5.03 On February 11, 2014, the Company’s third amended and restated certificate of incorporation, in substantially the form previously filed as Exhibit 3.1 to Pre-Effective Amendment No. 2 to the Company’s Registration Statement on Form S-1 (File No. 333-191759) (the “Registration Statement”), became effective. 8.01 On February 11, 2014, the Company issued a press release announcing the completion of its initial public offering of 4,200,000 shares of common stock (the “Shares”) for cash consideration of $12.00 per share (before underwriting discount) to a syndicate of underwriters led by Stifel Nicolaus & Company, Incorporated and JMP Securities LLC, acting as joint bookrunning managers. | a2218251z8-k.htm |